10:10 AM EDT, 07/08/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Monday it has received new patents in the European Union, Canada, and the US for antiviral drug delivery and epilepsy treatment.

The company said it received the EU patent for Transdermal and/or Dermal Delivery of Lipophilic Active Agents, validated in 10 countries, and expiring in 2039, if not extended.

In Canada, the company was awarded a new patent for Enhanced Delivery of Antiviral Agents, expiring in 2041 if not extended, and in the US, it received a patent for treating epilepsy, expiring in 2044 if not extended, Lexaria said.

Shares of Lexaria were down 1.3% in recent Monday trading.

Price: 2.70, Change: -0.04, Percent Change: -1.28